This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cornerstone Therapeutics Reacquires HMGB1 Protein Technology Platform

CARY, N.C., July 6 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX) ("Cornerstone"), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC ("MedImmune").  

This technology is licensed to Cornerstone from the Feinstein Institute for Medical Research and was the subject of a July 30, 2003 Exclusive License and Collaboration Agreement between Cornerstone and MedImmune that focused on the use of the technology by MedImmune in  developing antibodies that bind to the HMGB1 protein to reduce chronic inflammation associated with various medical conditions.  HMGB1 is a nuclear DNA-binding protein, which is elevated in the body following infection or trauma and may be an important factor when developing therapeutics to treat these conditions.  Unlike other previously identified cytokines, such as interleukin-1 and TNF-alpha, HMGB1 is expressed much later in the inflammatory response and persists at elevated levels in the bloodstream for a longer period of time.  With Cornerstone's broad intellectual property portfolio and proof of concept having been achieved for two pre-clinical models with human anti-HMGB1 monoclonal antibodies, this technology could potentially be utilized to develop alternative therapies in diseases of sterile inflammation, such as stroke, heart attack and arthritis, as well as infection inflammation, such as pneumonia, meningitis and sepsis.

Cornerstone intends to identify a partner in order to move the development of this technology platform forward.  The Company has not included any potential financial gain related to a possible out-license agreement for the HMGB1 protein technology in its 2010 guidance.

"While our strategic focus continues to be on acquiring and developing products for the respiratory and hospital markets, we believe that reacquiring these rights is a unique low-risk, high-reward opportunity for Cornerstone," said Craig A. Collard, Cornerstone's President and Chief Executive Officer.  "Several parties have expressed to us their interest in further developing this valuable platform.  We look forward to appropriately monetizing this asset, which would allow us to enhance our already strong balance sheet for possible product acquisition opportunities, as well as help fund the continued development of our internal drug pipeline."

About HMGB1

High-mobility group box protein 1 (HMGB1), a DNA-binding protein, regulates gene transcription and stabilizes nucleosome formation.  Elevated HMGB1 levels characterize various acute and chronic diseases and are implicated in inflammation and tissue injury.  In addition to its role as a transcription factor, HMG is a late endogenous mediator of tissue injury, initiated by pro-inflammatory cytokines.  HMG levels correlate with disease activity and rHMG induces injury and death.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CRTX $0.00 0.00%
AAPL $95.18 1.60%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.12 -4.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs